RESUMO
The SARS-CoV-2 virus is a virus that emerged in late 2019 and has yet to find a cure. On the other hand, the incidence of cervical cancer in women continues to increase along with the emergence of cases of COVID-19 caused by SARS-CoV-2. Based on WHO data in 2020 stated that there were 107 per 72,314 cancer patients infected with SARS-CoV-2. Meniran (Phyllanthus niruri L.) is a herbaceous plant in Indonesia that has secondary metabolites derived from the tannin group, such as corilagin. This compound has the potential to be developed as an antiviral and anticancer agent. Thus, the purpose of this study was to determine the potential of corilagin in meniran herbs to act as an antiviral SARS-CoV-2 and cervical anticancer compared to the drug compounds molnupiravir and paclitaxel through the STITCH & STRING bioinformatics in silico test and molecular docking method. The results of the bioinformatics test of corilagin against the SARS-CoV-2 virus showed predictions of high protein binding to AGTR2 and ENPEP with a docking score of -10.9 and -9.9 kcal/mol, respectively. Meanwhile, cervical cancer cells showed the highest predicted protein binding to IL-10 and MAPK3 with a docking score of -10.5 and -10.8 kcal/mol. The docking score of molnupiravir against the COVID-19 virus protein, AGTR2, and ENPEP were -7.4 and -7.2 kcal/mol, respectively. The docking scores of paclitaxel for IL10 and MAPK3 were -8.2 and -8.9 kcal/mol, respectively. These values indicate that the activity of corilagin with proteins AGTR2, ENPEP, IL10, and MAPK3 has stronger affinity energy than the comparison drugs molnupiravir and paclitaxel. Thus, the corilagin compound from the tannin group in meniran (Phyllanthus niruri L.) has the potential to be developed and formulated as a treatment and prevention of SARS-CoV-2 antiviral and cervical anticancer.
RESUMO
Obesity is a complex multi factorial preventable disease affecting all age groups of both the sexes. Now one third of world’s population is overweight or obese. From 1980 the world-wide prevalence of obesity has become doubled. Overweight and obesity were the 5th foremost causes of death globally. Obesity is associated with many co morbid diseases. Prevalence of obesity with co morbidities is on big alarm throughout the world. Recently in COVID-19 pandemic most of the obese people get affected due to the co morbidities and reduced immunity. The anti-obesity properties of medicinal plants were known from ancient times in traditional Siddha medicine some thousand years ago. Many Siddha medicinal plants showed anti-obesity activities that can be utilized in the management of obesity, through which the complications of obesity can be prevented. Most researches explored the anti-obesity potentials of medicinal plants. Terminalia chebula, Phyllanthus niruri, zingiber officinale, Piper longum, Curcuma longa, Elettaria cardamomum, Cuminum cyminum, Picrorhiza kurroa, Ipomea turpethum, Tinospora cordifolia, Michelia champaka are some medicinal plants possess anti-obesity properties that had been indicated in Siddha classical text. The objective of this review is to validate the anti-obesity potentials of Siddha medicinal plants scientifically through various research reports. Due to the presence of Phyto compounds like phenols, flavonoids, terpenoids, alkaloids, anti-oxidants these medicinal plants revealed anti-obesity activities and its anti-obesity mechanism had been proven scientifically through various animal experimental studies collected from many research articles. Modern anti-obesity drugs produce numerous side effects. Regular consumption of Siddha anti-obesity medicinal plants, in the prescribed dose and duration, can induce gradual and sustainable weight loss effectively. Furthermore, in future, there is a need for the development of standardized, safe and effective anti-obesity drugs from medicinal plants and highly economical too. Hence eventually exploration of anti-obesity Siddha medicinal plants will lead to safe and effective treatment for obesity.
RESUMO
OBJECTIVES: Phyllanthus niruri has been known as an immunomodulator and also reported to possess an antiviral activity against several RNA viruses, such as hepatitis B virus and hepatitis C virus by inhibiting viral entry and replication. Since the current situation of Coronavirus Disease 2019 (COVID-19) which infected among the world and caused severe disease and high morbidity, it urgently needed to find new agents against COVID-19. Therefore, in silico screening against COVID-19 receptors is carried out as an initial stage of drug discovery by evaluating the activity of phyllanthin and hypophyllanthin, an isolated from Phyllanthus niruri, in inhibiting spike glycoprotein (6LZG) and main protease (5R7Y) which play as target receptors of COVID-19. METHODS: Molegro Virtual Docker 6.0 used to determine the best binding energy through the rerank score which shows the total energy bonds calculation. RESULTS: Phyllanthin and hypophyllanthin demonstrated to possess greater binding affinity toward the COVID-19 inhibition sites than their native ligand. The rerank score of phyllanthin and hypophyllanthin are lower than the native ligands 6LZG and 5R7Y. This result indicated that phyllanthin and hypophyllanthin have a stronger interaction than the native ligands both in spike glycoprotein (entry inhibitor) and main protease (translation and replication inhibitor). CONCLUSIONS: In conclusion, phyllanthin and hypophyllanthin are predicted to have strong activity against COVID-19 through inhibiting spike glycoprotein and main protease under in silico study. Further research is needed to support the development of P. niruri as inhibitor agents of COVID-19 through bioassay studies.